Study Description
CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50%, and with no previous cardiovascular events.
The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated statin therapy in reducing total coronary atheroma volume assessed by coronary computed tomography angiography from baseline to month 24 in participants with a diagnosis of NOCAD without previous cardiovascular events, a CT-adapted Leaman score >5 and a FFRct >0.8. Participants will either receive inclisiran 300 mg subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months up until Month 21. The study duration is 24 months. Participants will have a CCTA performed at baseline and at the month 24/end of study visit.
Interventions
Inclisiran sodium 300 mg
Placebo
Eligibility Criteria
Inclusion Criteria:
Male or female ≥18 years or ≤80 years of age at signing of informed consent.
Fasting LDL-C local lab value at the Screening Visit of either i) ≥100 mg/dL if on statin therapy but not on a maximally tolerated statin therapy; ii) ≥150 mg/dL if statin naive and without documented statin intolerance; or iii) ≥70 mg/dL if on a stable (≥4 weeks) dose of maximally tolerated statin therapy or if statin intolerant.
Participants may be pre-identified based on a CCTA or an invasive angiography that is performed as part of standard of care within 12 months prior to the participant's Screening Visit demonstrating:
Presence of coronary artery plaque with visual diameter stenosis <50% or
Coronary artery plaque with visual artery stenosis >50% but Fractional Flow Reserve (FFR) >0.8 by special wire measurement (CCTA or coronary angiography)
Fasting LDL-C local lab value ≥70 mg/dL at the assessment performed during the Statin Optimization Period 3 Visit for participants going through the Statin Optimization Period.
Participants having Non-Obstructive Coronary Artery (NOCA)* confirmed by CCTA with FFRct >0.8 and CT-adapted Leaman score >5** or coronary artery plaque with visual diameter stenosis >50% but with FFRct >0.8 and CT-adapted Leaman score >5 without previous cardiovascular events.
*=NOCA is defined as the presence of coronary artery plaque with visual diameter stenosis <50%.
**=CT-adapted Leaman score, which includes information on lesion localization, plaque composition, degree of stenosis by CCTA is demonstrated to be an independent long-term predictor of hard cardiac events.
A standard of care CCTA may serve as the study baseline CCTA scan if it is performed within 3 months prior to the participant's Screening Visit and meets the inclusion criteria of FFRct >0.8 and CT-adapted Leaman score >5, which will be assessed by the Imaging Core Lab.
At the Baseline Visit, participants must be on a stable (≥4 weeks) dose of maximally tolerated statin therapy. Participants not on maximally tolerated statin therapy and who do not have documented statin intolerance can be screened but must enter the study via a Statin Optimization Period.
Exclusion Criteria:
Previous cardiovascular events history including myocardial infarction (MI), or prior coronary revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)].
Planned revascularization (PCI) or (CABG).
Previous cerebrovascular events including:
Prior ischemic stroke thought not to be caused by atrial fibrillation, valvular heart disease or mural thrombus.
History of prior percutaneous or surgical carotid artery revascularization.
History of Peripheral Artery Disease (PAD):
Prior documentation of a resting ankle-brachial index <0.85.
History of prior percutaneous or surgical revascularization of an iliac, femoral, or popliteal artery.
Prior non-traumatic amputation of a lower extremity due to peripheral artery disease.
Cardiac disorders, including any of the following:
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, atrial fibrillation) within 3 months prior to randomization that is not controlled by medication or via ablation at the time of the Screening Visit.
Complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) prior to randomization.
NOCA participant who was prescreened by the Investigator with visual diameter stenosis >50% but FFR <0.8.
Contraindication for CCTA (e.g., allergic reactions to the contrast dye) or CCTA not meeting entry standards after two attempts during the Baseline CCTA Visit as assessed by the Imaging Core Lab.
Pacemaker or implantable cardioverter-defibrillator (ICD) in situ.
Systolic Left Ventricle Ejection Fraction <30% at the Screening Visit.
Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization (assessed at the Screening Visit) despite antihypertensive therapy.
Heart failure New York Heart Association (NYHA) class III or class IV at the Screening Visit.
Renal insufficiency (eGFR <30 mL/min/1.73m2) as measured by the Modification of Diet in Renal Disease (MDRD) formula at the Screening Visit and at the Statin Optimization 3 Visit.
Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver at the Screening Visit. Participants who enter the Statin Optimization Period must have AST and ALT ≤3x ULN (as defined by local laboratory reference ranges collected at the Screening Visit) and reported by the Statin Optimization Telephone Visit 1 to be allowed to continue in the Statin Optimization Period.
Study Location
Novartis Investigative Site
Recruiting
Ciudad Autonoma de Bs As,Buenos Aires,C1119ACN,Argentina
Novartis Investigative Site
Recruiting
Buenos Aires,C1428DCO,Argentina
Novartis Investigative Site
Recruiting
Leabrook,South Australia,5068,Australia
Novartis Investigative Site
Recruiting
Chemside,Queensland,4032,Australia
Novartis Investigative Site
Recruiting
Milton,Queensland,4064,Australia
Novartis Investigative Site
Recruiting
Auchenflower,Queensland,4066,Australia
Novartis Investigative Site
Recruiting
Yvoir,5530,Belgium
Novartis Investigative Site
Recruiting
Aalst,9300,Belgium
Novartis Investigative Site
Recruiting
Hasselt,3500,Belgium
Novartis Investigative Site
Recruiting
Turnhout,2300,Belgium
Novartis Investigative Site
Recruiting
Genk,3600,Belgium
Novartis Investigative Site
Recruiting
Curitiba,PR,80040-050,Brazil
Novartis Investigative Site
Recruiting
Sao Paulo,01409-902,Brazil
Novartis Investigative Site
Recruiting
Porto Alegre,RS,90560 030,Brazil
Novartis Investigative Site
Recruiting
Montreal,Quebec,H1T 1C8,Canada
Novartis Investigative Site
Recruiting
North York,Ontario,M6B 3H7,Canada
Novartis Investigative Site
Recruiting
Ottawa,Ontario,K1Y 4W7,Canada
Novartis Investigative Site
Recruiting
Temuco,Region De La Araucania,4781156,Chile
Novartis Investigative Site
Recruiting
Santiago,RM,8380465,Chile
Novartis Investigative Site
Recruiting
Beijing,100029,China
Novartis Investigative Site
Recruiting
Hangzhou,Zhejiang,310016,China
Novartis Investigative Site
Recruiting
Beijing,100050,China
Novartis Investigative Site
Recruiting
Shanghai,200080,China
Novartis Investigative Site
Recruiting
Nanjing,Jiangsu,211166,China
Novartis Investigative Site
Recruiting
Paris,75015,France
Novartis Investigative Site
Recruiting
Pessac Cedex,33604,France
Novartis Investigative Site
Recruiting
Toulouse 4,31054,France
Novartis Investigative Site
Recruiting
Poitiers,86021,France
Novartis Investigative Site
Recruiting
Paris 13,75651,France
Novartis Investigative Site
Recruiting
Budapest,1085,Hungary
Novartis Investigative Site
Recruiting
Szeged,6720,Hungary
Novartis Investigative Site
Recruiting
New Delhi,Delhi,110 017,India
Novartis Investigative Site
Recruiting
New Delhi,Delhi,110 060,India
Novartis Investigative Site
Recruiting
DehraDun,Uttarakhand,248001,India
Novartis Investigative Site
Recruiting
Chennai,Tamil Nadu,600006,India
Novartis Investigative Site
Recruiting
New Delhi,110025,India
Novartis Investigative Site
Recruiting
Lucknow,Uttar Pradesh,226003,India
Novartis Investigative Site
Recruiting
Coimbatore,641 009,India
Novartis Investigative Site
Recruiting
Bangalore,Karnataka,560 069,India
Novartis Investigative Site
Recruiting
Dublin,94568,Ireland
Novartis Investigative Site
Recruiting
Galway,H91,Ireland
Novartis Investigative Site
Recruiting
Milano,MI,20138,Italy
Novartis Investigative Site
Recruiting
Torino,TO,10126,Italy
Novartis Investigative Site
Recruiting
Milano,MI,20157,Italy
Novartis Investigative Site
Recruiting
Rozzano,MI,20089,Italy
Novartis Investigative Site
Recruiting
Miyhazaki-city,Miyazaki,880-2102,Japan
Novartis Investigative Site
Recruiting
Izumisano-city,Osaka,598-8577,Japan
Novartis Investigative Site
Recruiting
Urasoe,Okinawa,901-2102,Japan
Novartis Investigative Site
Recruiting
Kumamoto City,Kumamoto,860-8556,Japan
Novartis Investigative Site
Recruiting
Kyoto-city,Kyoto,607-8062,Japan
Novartis Investigative Site
Recruiting
Goyang si,Gyeonggi Do,10380,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,03722,Korea, Republic of
Novartis Investigative Site
Recruiting
Seoul,07804,Korea, Republic of
Novartis Investigative Site
Recruiting
Bundang Gu,Gyeonggi Do,13620,Korea, Republic of
Novartis Investigative Site
Recruiting
Barcelona,08041,Spain
Novartis Investigative Site
Recruiting
A Coruna,Galicia,15006,Spain
Novartis Investigative Site
Recruiting
Madrid,28034,Spain
Novartis Investigative Site
Recruiting
Cordoba,Andalucia,14004,Spain
Novartis Investigative Site
Recruiting
Valencia,Comunidad Valenciana,46010,Spain
Novartis Investigative Site
Recruiting
Madrid,28040,Spain
Novartis Investigative Site
Recruiting
Barcelona,Catalunya,08035,Spain
Novartis Investigative Site
Recruiting
Salamanca,Castilla Y Leon,37007,Spain
Novartis Investigative Site
Recruiting
Valencia,Comunidad Valenciana,46014,Spain
Novartis Investigative Site
Recruiting
Lugano,6903,Switzerland
Novartis Investigative Site
Recruiting
Geneve 14,1211,Switzerland
Novartis Investigative Site
Recruiting
London,SE5 9RS,United Kingdom
Novartis Investigative Site
Recruiting
Bradford,West Yorkshire,BD9 6RJ,United Kingdom
Novartis Investigative Site
Recruiting
Edinburgh,EH16 4SA,United Kingdom
Novartis Investigative Site
Recruiting
Newcastle upon Tyne,NE7 7DN,United Kingdom
Novartis Investigative Site
Recruiting
Craigavon,Northern Ireland,BT63 5QQ,United Kingdom
Stanford Health Care .
Recruiting
Stanford,Sarah Magee (650-924-0851) email: [email protected] -- Koen Nieman,94305 - California,United States
Anderson Medical Research Main Center
Recruiting
Fort Washington,Felton Anderson,20744 - Maryland,United States
NorthShore University Health System .
Recruiting
Evanston,Mitchell Cyganiak (646-345-1642) email: [email protected] -- Amit Pursnani,60201 - Illinois,United States
Virginia Heart
Recruiting
Falls Church,Claudia Diaz (703-766-5920) email: [email protected] -- Tariq Haddad,22042 - Virginia,United States
Icahn School of Med at Mt Sinai .
Recruiting
New York,Jay Krishna Katragadda (+1 212 659 9174) email: [email protected] -- Robert Rosenson,10029 - New York,United States
State Uni of NY at Stony Brook .
Recruiting
Stony Brook,Uzma Usmani email: [email protected] -- On Chen,11794-3362 - New York,United States
Aultman Hospital Main Centre
Recruiting
Canton,Jennifer Bajornas (330-489-9053) email: [email protected] -- Brendan Duffy,44710 - Ohio,United States
Oregon Health Sciences University Main Center
Recruiting
Portland,Rosa Woo (503-494-8311) email: [email protected] -- Maros Ferencik,97239 - Oregon,United States
Washington Hospital Center Medstar
Recruiting
Washington,Donna Whitman (202-877-7066) email: [email protected] -- Ron Waksman,20010 - District of Columbia,United States
Lankenau Hospital
Recruiting
Wynnewood,Stephanie Wright (484-476-8579) email: [email protected] -- Erik Kelly,19096 - Pennsylvania,United States
Swedish Medical Ctr Cardiovascular Re .
Recruiting
Seattle,Andrew Buysse (206-861-8550) email: [email protected] -- Santanu Biswas,98122 - Washington,United States
Bridgeport Hospital .
Recruiting
Bridgeport,Brenda Garcia (203-384-4849) email: [email protected] -- Adam Schussheim,06610 - Connecticut,United States
Orion Medical
Recruiting
Houston,Luisa Castelan (713-943-2800) email: [email protected] -- Karan Bhalla,77034 - Texas,United States
Westchester Medical Center .
Recruiting
Valhalla,(914-909-6900) -- Hasan Ahmad,10595 - New York,United States
Lundquist Inst BioMed at Harbor UCLA Medical Center
Recruiting
Torrance,Khadije Ahmad (+1 310 222 4107) email: [email protected] -- Matthew Jay Budoff,90509-2910 - California,United States
The Uni of Kansas Medical Center
Recruiting
Kansas City,Rebecca Johnson (913-588-9722) email: [email protected] -- Thomas Rosamond,66160 - Kansas,United States
Cardio Metabolic Institute Research
Recruiting
Somerset,Ashley Hansen (+1 732 846 7000 #108) email: [email protected] -- Dinesh Singal,08873 - New Jersey,United States
R Ins For Heart And Vascular Health .
Recruiting
Reno,Lisa Preciado (775-982-5443) email: [email protected] -- Thomas Duythuc To,89502 - Nevada,United States
MCVI Baptist Hlth of S FL
Recruiting
Miami,Ruben Dominguez email: [email protected] -- Jonathan A Fialkow,33173 - Florida,United States
U of Louisville Rudd Heart and Lung
Recruiting
Louisville,Jennifer Moore (502-852-1826) email: [email protected] -- Dinesh Kalra,40202 - Kentucky,United States
Cardiovascular Res Found
Recruiting
Beverly Hills,Juan Ramos (310-278-3400) email: [email protected] -- Ronald P Karlsberg,90210 - California,United States
Reid Physician Associates
Recruiting
Richmond,Nancy Fry (765-962-1337) email: [email protected] -- John McGinty,47374 - Indiana,United States
Midwest Heart and Vascular Spec .
Recruiting
Overland Park,Chelsea Waller (919-253-5000) email: [email protected] -- Stephen Bloom,66211 - Kansas,United States
George Washington Univ Medical Ctr
Recruiting
Washington,Priscilla Muhanji (202-741-2293) email: [email protected] -- Andrew Choi,20037 - District of Columbia,United States
UC San Diego Health .
Recruiting
La Jolla,Marissa Dzotsi email: [email protected] -- Michael John Wilkinson,92037 - California,United States
Alaska Heart and Vascular
Recruiting
Anchorage,Heather Craven (907-561-3211) email: [email protected] -- Jacob Kelly,99508 - Alaska,United States
Soltero Cardiovascular Research Ctr .
Recruiting
Dallas,Natalia Feliz (214-820-2273) email: [email protected] -- Cara East,75226 - Texas,United States
Minneapolis Heart Institute
Recruiting
Minneapolis,Haley Hanson (612-863-3900) email: [email protected] -- Jonathan Urbach,55407 - Minnesota,United States
Heart Center Research Llc .
Recruiting
Huntsville,Carolyn Keefer (256-519-8255) email: [email protected] -- Michael Ridner,35801 - Alabama,United States
Univ of Washington Medical Center .
Recruiting
Seattle,Kevin Palacpac (206-543-9782) email: [email protected] -- Kelley Branch,98195 - Washington,United States
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.